SG10201912521PA - Methods of diagnosing and treating abiraterone acetate- glucocorticoid -resistant or -sensitive metastatic castration resistant prostate cancer - Google Patents

Methods of diagnosing and treating abiraterone acetate- glucocorticoid -resistant or -sensitive metastatic castration resistant prostate cancer

Info

Publication number
SG10201912521PA
SG10201912521PA SG10201912521PA SG10201912521PA SG10201912521PA SG 10201912521P A SG10201912521P A SG 10201912521PA SG 10201912521P A SG10201912521P A SG 10201912521PA SG 10201912521P A SG10201912521P A SG 10201912521PA SG 10201912521P A SG10201912521P A SG 10201912521PA
Authority
SG
Singapore
Prior art keywords
resistant
glucocorticoid
diagnosing
methods
prostate cancer
Prior art date
Application number
SG10201912521PA
Inventor
Kazushiro Kawaguchi
Ryo Oyama
Weimin Li
Jaymala Patel
Denis Smirnov
Original Assignee
Janssen Pharmaceutica Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv
Publication of SG10201912521PA publication Critical patent/SG10201912521PA/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/56Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/56Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407Specifically defined cancers
    • G01N33/57434Specifically defined cancers of prostate
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00Oligonucleotides characterized by their use
    • C12Q2600/158Expression markers
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/575Hormones
    • G01N2333/5755Neuropeptide Y
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90Enzymes; Proenzymes
    • G01N2333/902Oxidoreductases (1.)
    • G01N2333/90206Oxidoreductases (1.) acting on the CH-CH group of donors (1.3)
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90Enzymes; Proenzymes
    • G01N2333/91Transferases (2.)
    • G01N2333/91045Acyltransferases (2.3)
    • G01N2333/91074Aminoacyltransferases (general) (2.3.2)
    • G01N2333/9108Aminoacyltransferases (general) (2.3.2) with definite EC number (2.3.2.-)
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90Enzymes; Proenzymes
    • G01N2333/914Hydrolases (3)
    • G01N2333/948Hydrolases (3) acting on peptide bonds (3.4)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Physics & Mathematics (AREA)
  • Hospice & Palliative Care (AREA)
  • Oncology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Cell Biology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Steroid Compounds (AREA)
SG10201912521PA 2016-09-30 2017-09-29 Methods of diagnosing and treating abiraterone acetate- glucocorticoid -resistant or -sensitive metastatic castration resistant prostate cancer SG10201912521PA (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201662402196P 2016-09-30 2016-09-30

Publications (1)

Publication Number Publication Date
SG10201912521PA true SG10201912521PA (en) 2020-02-27

Family

ID=60186369

Family Applications (1)

Application Number Title Priority Date Filing Date
SG10201912521PA SG10201912521PA (en) 2016-09-30 2017-09-29 Methods of diagnosing and treating abiraterone acetate- glucocorticoid -resistant or -sensitive metastatic castration resistant prostate cancer

Country Status (15)

Country Link
US (1) US20180092930A1 (en)
EP (1) EP3519591A1 (en)
JP (1) JP7197470B2 (en)
KR (1) KR20190056420A (en)
CN (1) CN109790586A (en)
AU (1) AU2017336917A1 (en)
BR (1) BR112019006404A2 (en)
CA (1) CA3038964A1 (en)
EA (1) EA201990847A1 (en)
IL (1) IL265675A (en)
JO (1) JOP20190067A1 (en)
MX (1) MX2019003731A (en)
PH (1) PH12019500675A1 (en)
SG (1) SG10201912521PA (en)
WO (1) WO2018064470A1 (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7496975B2 (en) * 2019-12-27 2024-06-10 富士フイルム株式会社 Methods for aiding in the diagnosis of metastatic castration-resistant prostate cancer - Patents.com
CN111500728A (en) * 2020-05-13 2020-08-07 无锡市申瑞生物制品有限公司 Primer probe composition, kit and detection method for detecting human AR-V7 and AR gene expression
WO2022067185A1 (en) * 2020-09-27 2022-03-31 Veru Inc. Methods of treating prostate cancer with minimal side effects

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014008155A1 (en) * 2012-07-02 2014-01-09 The General Hospital Corporation Diagnosis and monitoring treatment of prostate cancer
WO2014016830A1 (en) * 2012-07-25 2014-01-30 Mapi Pharma Ltd. Process and intermediates for the preparation of abiraterone acetate
JOP20200097A1 (en) * 2013-01-15 2017-06-16 Aragon Pharmaceuticals Inc Androgen receptor modulator and uses thereof
US20150246060A1 (en) * 2013-03-15 2015-09-03 Iceutica Inc. Abiraterone Acetate Formulation and Methods of Use
WO2015024664A1 (en) * 2013-08-21 2015-02-26 Curevac Gmbh Composition and vaccine for treating prostate cancer
US20150110814A1 (en) * 2013-10-18 2015-04-23 Psma Development Company, Llc Combination therapies with psma ligand conjugates
US20150147339A1 (en) * 2013-11-15 2015-05-28 Psma Development Company, Llc Biomarkers for psma targeted therapy for prostate cancer
ES2919098T3 (en) * 2014-01-27 2022-07-21 Epic Sciences Inc Detection of prostate-specific membrane antigen (PSMA) expression in circulating tumor cells (CTCs)
JP6735236B2 (en) * 2014-05-12 2020-08-05 ヤンセン ファーマシューティカ エヌ.ベー. Biological markers for identifying patients for treatment with abiraterone acetate

Also Published As

Publication number Publication date
EA201990847A1 (en) 2019-08-30
CN109790586A (en) 2019-05-21
US20180092930A1 (en) 2018-04-05
PH12019500675A1 (en) 2019-12-02
CA3038964A1 (en) 2018-04-05
EP3519591A1 (en) 2019-08-07
MX2019003731A (en) 2019-07-01
AU2017336917A1 (en) 2019-04-11
JP2019530452A (en) 2019-10-24
WO2018064470A1 (en) 2018-04-05
JOP20190067A1 (en) 2019-03-28
JP7197470B2 (en) 2022-12-27
IL265675A (en) 2019-05-30
BR112019006404A2 (en) 2019-06-25
KR20190056420A (en) 2019-05-24

Similar Documents

Publication Publication Date Title
HK1253093A1 (en) Methods of diagnosing and treating cancer
IL271888A (en) Therapeutic and diagnostic methods for cancer
IL265759A (en) Therapeutic and diagnostic methods for cancer
IL268396A (en) Diagnostic and therapeutic methods for cancer
IL275663A (en) Methods of treating cancer
IL274246A (en) Diagnostic and therapeutic methods for cancer
IL261422A (en) Therapeutic and diagnostic methods for cancer
IL262208A (en) Diagnostic and therapeutic methods for cancer
IL265697B1 (en) Treatment of prostate cancer
IL248487A0 (en) Methods of treating early breast cancer with trastuzumab-mcc-dm1 and pertuzumab
IL273071A (en) Diagnostic and therapeutic methods for cancer
IL266990A (en) Methods of treating cancer using anti-pd-l1 antibodies and antiandrogens
IL264443A (en) Methods of treating prostate cancer
IL273919A (en) Anti-androgens for the treatment of non-metastatic castration-resistant prostate cancer
IL273196A (en) Claudin6 antibodies and methods of treating cancer
IL244421A0 (en) Methods and kits for predicting outcome and methods and kits for treating breast cancer with radiation therapy
IL276748A (en) Methods for prostate cancer detection and treatment
IL263562A (en) Methods and compositions for prostate cancer diagnosis and treatment
IL272810A (en) Methods of diagnosing and treating lung cancer
ZA202006008B (en) Psma-targeted radiopharmaceutical for diagnosing and treating prostate cancer
IL265675A (en) Methods of diagnosing and treating abiraterone acetate- glucocorticoid -resistant or -sensitive metastatic castration resistant prostate cancer
IL275517A (en) Methods and combination therapy to treat cancer
SG11202005163PA (en) Methods of treating cancer
IL269123A (en) Methods of treating cancer
IL276985A (en) Methods of diagnosing and treating bladder cancer